Arch Biopartners Announces Non Brokered Private Placement Financing

- January 26th, 2018

Arch Biopartners (TSXV:ARCH) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000 common shares priced at $0.50 per common share for gross proceeds of up to $1,250,000. As quoted in the press release: The Company intends to use a portion of the proceeds from the private placement … Continued

Arch Biopartners (TSXV:ARCH) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000 common shares priced at $0.50 per common share for gross proceeds of up to $1,250,000.

As quoted in the press release:

The Company intends to use a portion of the proceeds from the private placement to complete the funding of the investigator initiated Phase I inhalation safety trial Arch is sponsoring for AB569 at the Cincinnati Veterans Affairs Medical Center. AB569 is the Company’s drug candidate for treating drug resistant bacterial infections in the lungs and urinary tract.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply